2025-11-16 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the data you provided.

## Hims & Hers Health Inc. (HIMS) Analysis

**Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers a variety of health and wellness products and services directly to consumers.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (HIMS):** 140.64%
*   **Cumulative Return (VOO):** 72.58%
*   **Absolute Divergence:** 68.06%
*   **Relative Divergence:** 49.7 (Indicates HIMS's performance is in the upper range of its historical divergence from VOO.)

**Analysis:** HIMS has significantly outperformed the S&P 500. The relative divergence of 49.7 suggests that while HIMS has had periods of both outperformance and underperformance, its current outperformance is positioned in the upper half of its historical range relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| :---------- | :----- | :----- | :----- | :---- | :----- |
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.4    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0   | 1.4    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1   | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0   | 5.4    |
| 2023-2025  | 145.0% | 80.8% | 82.0%  | 0.1   | 8.2    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows a wide range of performance.  The early periods show significant negative CAGR, while the later periods (2022-2025, 2023-2025) show very strong positive growth.  This suggests a volatile stock with recent strong upward momentum.
*   **MDD:**  The Maximum Drawdown is consistently high, indicating significant risk and price volatility.
*   **Alpha:** Alpha values are mostly negative initially but turn positive in the most recent periods.  This suggests that the company has recently begun to outperform its expected return based on its beta.
*   **Beta:** Beta is around 0, suggesting that the stock is not strongly correlated with the overall market.
*   **Cap(B):**  Market capitalization has been growing over the observed periods, reflecting the company's growth.

### 2. Recent Stock Price Movements

*   **Current Price:** $36.98
*   **Previous Close:** $36.05
*   **Change:** +2.58%
*   **5-Day Moving Average:** $38.57
*   **20-Day Moving Average:** $44.16
*   **60-Day Moving Average:** $49.62

**Analysis:** The stock price has increased recently (+2.58% from the previous close). However, the price is below all moving averages (5, 20, and 60-day), suggesting a short-term downward trend despite the recent uptick. The fact that price increased substantially relative to the previous close may indicate a reaction to news.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 18.45 (Oversold)
*   **PPO:** -1.8075
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Delta_Previous_Relative_Divergence (20-day):** -5.2 (Negative trend in relative performance)
*   **Expected Return:** 8.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates the stock is currently oversold, which could signal a potential buying opportunity.
*   The PPO indicates that the price has fallen too fast and it will rebound.
*   The negative change in relative divergence suggests recent underperformance compared to the S&P 500.
*   The Hybrid Signal suggests a buying opportunity.
*   The expected return of 8.9% is attractive, indicating potential long-term outperformance.
*   The recent price change may be related to news.

### 4. Recent News & Significant Events

*   **Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death:** This is a significant negative headline and could impact investor sentiment and potentially lead to legal challenges.
*   **Hims & Hers Bets on Lab Testing to Boost Growth:**  This indicates a strategic move to expand service offerings and potentially increase revenue.
*   **Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience:**  Further confirms the expansion into lab testing.
*   **Healthcare Stock to Consider Right Now and 2 Facing Headwinds & Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors:** These articles suggest mixed sentiment on HIMS.

**Analysis:** The news is mixed. The expansion into lab testing is a positive development. The lawsuit regarding mental healthcare is a major concern. The analyst articles suggest both positive and negative perspectives.

### 4-2. Analyst Opinions

*   **Consensus:** Hold (2.86)
*   **Target Price (Avg/High/Low):** $46.67 / $85.00 / $25.00

**Analysis:** The consensus rating is "Hold," suggesting analysts are neutral on the stock. The average target price is higher than the current price, implying potential upside. However, the wide range between the high and low target prices indicates uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출      |
| :----------- | :--- | :-------- |
| 2025-11-03 | 0.07 | 0.60 B$   |
| 2025-08-04 | 0.19 | 0.54 B$   |
| 2025-05-05 | 0.22 | 0.59 B$   |
| 2024-11-04 | 0.35 | 0.40 B$   |
| 2025-11-03 | 0.35 | 0.40 B$   |

**Analysis:** Recent earnings show mixed results. While revenue has generally been increasing, EPS has fluctuated. The most recent EPS is lower than previous periods, but revenue is higher than some previous quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :----------- | :--------- | :-------------- |
| 2025-09-30 | $0.60B     | 73.80%          |
| 2025-06-30 | $0.54B     | 76.39%          |
| 2025-03-31 | $0.59B     | 73.50%          |
| 2024-12-31 | $0.48B     | 76.81%          |
| 2024-09-30 | $0.40B     | 79.16%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
| :----------- | :--------- | :------ |
| 2025-09-30 | $0.58B     | 2.72%   |
| 2025-06-30 | $0.56B     | 7.55%   |
| 2025-03-31 | $0.55B     | 9.01%   |
| 2024-12-31 | $0.48B     | 5.46%   |
| 2024-09-30 | $0.44B     | 17.18%  |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing over the past year, indicating strong growth.
*   **Profit Margin:** Profit margins are high and relatively stable, suggesting good operational efficiency.
*   **Equity:** Equity has been increasing, indicating a strengthening financial position.
*   **ROE:** ROE has fluctuated but generally decreased, indicating that the company is generating less profit from shareholders' equity compared to previous periods.

### 7. Overall Analysis and Recommendations

**Summary:** Hims & Hers Health Inc. (HIMS) is a high-growth, volatile stock. It has significantly outperformed the S&P 500, but carries significant risk.

**Positives:**

*   Strong revenue growth and high profit margins.
*   Strategic expansion into lab testing.
*   Oversold RSI may present a short-term buying opportunity.
*   Positive long-term expected return.
*   Recent stock price increase.

**Negatives:**

*   Lawsuit regarding mental healthcare is a major concern.
*   High volatility and maximum drawdown.
*   Decreasing ROE.
*   Analyst consensus is "Hold," with a wide range of target prices.
*   Negative trend in relative divergence.

**Recommendations:**

*   **Risk-tolerant investors:** The potential for high returns may be attractive. Consider starting a small position and averaging in over time to mitigate risk.
*   **All investors:** Closely monitor the lawsuit and any developments related to it. Pay attention to future earnings reports and revenue growth. Carefully consider the analyst ratings and target prices, but also be aware of the wide range of opinions.
*   Given the potential negative publicity and legal ramifications of the recent lawsuit, caution is warranted.

**Disclaimer:** This is an analysis based solely on the provided data and should not be considered financial advice. Consult with a financial professional before making any investment decisions.
